Standard BioTools Inc. Operating Lease Cost
Standard BioTools Inc. (LAB) reported Operating Lease Cost of $7.89 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-16.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseCost · last filed 2026-03-16
- Standard BioTools Inc. operating lease, cost for the quarter ending 2024-12-31 was $468.00K, a 76.48% decline year-over-year.
- Standard BioTools Inc. operating lease, cost for the quarter ending 2024-09-30 was $2.39M, a 19.66% increase year-over-year.
- Standard BioTools Inc. operating lease, cost for the quarter ending 2024-06-30 was $2.54M, a 27.04% increase year-over-year.
- Standard BioTools Inc. operating lease, cost for the quarter ending 2024-03-31 was $2.56M, a 27.16% increase year-over-year.
- Standard BioTools Inc. operating lease, cost for fiscal 2025 was $7.89M, a 0.78% decline from fiscal 2024.
- Standard BioTools Inc. operating lease, cost for fiscal 2024 was $7.95M, a 0.54% decline from fiscal 2023.
- Standard BioTools Inc. operating lease, cost for fiscal 2023 was $8.00M, a 0.10% increase from fiscal 2022.
- Standard BioTools Inc. operating lease, cost for fiscal 2022 was $7.99M, a 26.85% decline from fiscal 2021.
| Period end | Operating Lease, Cost 3 month | Operating Lease, Cost 6 month | Operating Lease, Cost 9 month | Operating Lease, Cost 12 month | Operating Lease, Cost 12 month as first filed |
|---|---|---|---|---|---|
| 2025-12-31 | $7.89M 10-K · filed 2026-03-16 | ||||
| 2024-12-31 | $468.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $2.85M derived: sum of 2 quarters · filed 2026-03-16 | $5.40M derived: sum of 3 quarters · filed 2026-03-16 | $7.95M 10-K · filed 2026-03-16 | $9.87M 10-K · filed 2025-03-11 |
| 2024-09-30 | $2.39M 10-Q · filed 2024-11-06 | $4.93M derived: sum of 2 quarters · filed 2024-11-06 | $7.48M 10-Q · filed 2024-11-06 | $9.47M derived: sum of 4 quarters · filed 2026-03-16 | |
| 2024-06-30 | $2.54M 10-Q · filed 2024-08-06 | $5.10M 10-Q · filed 2024-08-06 | $7.09M derived: sum of 3 quarters · filed 2026-03-16 | $9.08M derived: sum of 4 quarters · filed 2026-03-16 | |
| 2024-03-31 | $2.56M 10-Q · filed 2024-05-09 | $4.55M derived: sum of 2 quarters · filed 2026-03-16 | $6.54M derived: sum of 3 quarters · filed 2026-03-16 | $8.54M derived: sum of 4 quarters · filed 2026-03-16 | |
| 2023-12-31 | $1.99M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $3.98M derived: sum of 2 quarters · filed 2026-03-16 | $5.99M derived: sum of 3 quarters · filed 2026-03-16 | $8.00M 10-K · filed 2026-03-16 | $11.16M 10-K · filed 2024-03-01 |
| 2023-09-30 | $1.99M 10-Q · filed 2024-11-06 | $4.00M derived: sum of 2 quarters · filed 2024-11-06 | $6.00M 10-Q · filed 2024-11-06 | ||
| 2023-06-30 | $2.00M 10-Q · filed 2024-08-06 | $4.01M 10-Q · filed 2024-08-06 | |||
| 2023-03-31 | $2.01M 10-Q · filed 2024-05-09 | ||||
| 2022-12-31 | $7.99M 10-K · filed 2025-03-11 | $10.92M 10-K · filed 2023-03-14 | |||
| 2021-12-31 | $10.92M 10-K · filed 2023-03-14 | ||||
| 2020-12-31 | $2.67M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-08 | $5.17M derived: sum of 2 quarters · filed 2022-03-08 | $7.48M derived: sum of 3 quarters · filed 2022-03-08 | $9.68M 10-K · filed 2022-03-08 | |
| 2020-09-30 | $2.50M 10-Q · filed 2020-11-09 | $4.81M derived: sum of 2 quarters · filed 2020-11-09 | $7.01M 10-Q · filed 2020-11-09 | $8.45M derived: sum of 4 quarters · filed 2021-02-25 | |
| 2020-06-30 | $2.31M 10-Q · filed 2020-08-07 | $4.51M 10-Q · filed 2020-08-07 | $5.94M derived: sum of 3 quarters · filed 2021-02-25 | $7.55M derived: sum of 4 quarters · filed 2021-02-25 | |
| 2020-03-31 | $2.20M 10-Q · filed 2020-05-11 | $3.63M derived: sum of 2 quarters · filed 2021-02-25 | $5.24M derived: sum of 3 quarters · filed 2021-02-25 | $6.79M derived: sum of 4 quarters · filed 2021-02-25 | |
| 2019-12-31 | $1.43M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $3.04M derived: sum of 2 quarters · filed 2021-02-25 | $4.59M derived: sum of 3 quarters · filed 2021-02-25 | $6.09M 10-K · filed 2021-02-25 | |
| 2019-09-30 | $1.60M 10-Q · filed 2020-11-09 | $3.16M derived: sum of 2 quarters · filed 2020-11-09 | $4.66M 10-Q · filed 2020-11-09 | ||
| 2019-06-30 | $1.55M 10-Q · filed 2020-08-07 | $3.06M 10-Q · filed 2020-08-07 | |||
| 2019-03-31 | $1.50M 10-Q · filed 2020-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |